Oblato, Inc. (‘Oblato’ or ‘Company’) is a pharmaceutical company focused on the development and commercialization of novel cancer therapeutics to improve the quality of a patient’s life. Oblato is a wholly-owned subsidiary of the Korean biotech company HLB Therapeutics (formerly GtreeBNT).
Since acquiring OKN-007 (disufenton sodium), a nitrone derivative, from the Oklahoma Medical Research Foundation (OMRF) in 2016, Oblato has been developing it for the treatment of brain cancers, especially, for rare cancers, including glioblastoma multiforme (GBM) and a pediatric glioma known as diffuse intrinsic pontine glioma (DIPG).
OKN-007 is a free radical scavenger that eliminates reactive oxygen species and reduces necrosis, hypoxia, inflammation, and angiogenesis, thus normalizing the tumor microenvironment that drives glioblastoma growth.
Currently, clinical trials are ongoing to investigate the safety and efficacy of a combination therapy with both OKN-007 and temozolomide for patients with both newly diagnosed and recurrent GBM. Oblato also plans to conduct a clinical trial for DIPG with OKN-007 in combination with standard of care radiotherapy.
Oblato will continue to look for ways to develop improved innovative treatments for patients suffering from rare cancers. Our research is making progress in identifying game-changing therapies that precisely target the disease and have fewer side effects than those observed with current cancer therapies. We are working hard to make such therapies available to the public.